biotechnology

Like all good venture capitalists, I started my career in the trenches working on the front line of my target industry, as a molecular biologist at LaTrobe University....

At midnight a couple of days ago the US Food and Drug Administration announced the approval of Biogen's Alzheimer's drug Aducanumab. Usually, when a drug is approved...

A look at the performance of the pharmaceutical and biotech sector over the month of April, along with companies in the IIR Pharma & Biotech Index that are trading at...

For all the leaps and bounds in medical science, the know-how behind detecting diseases hasn’t changed much in decades – or even centuries. Take X-rays, which are...

Normally investors shun speculative plays in times of market uncertainties, but that’s not been the case with ASX-listed life sciences stocks across the drug,...

The coronavirus has pulled the plug on many proposed initial public offers (IPOs), with the Australian Securities Exchange’s ‘upcoming listings’ feed looking decidedly...

Also available on iTunes or Spotify. Alexander Portz (LinkedIn) began his career investing in technology for UK funds management giant Neptune, before joining...

Technology may typically be thought of in terms of computers and communications but its use in the sphere of biotechnology is saving lives and changing how we treat...

Who said capitalism was dead in the new world order of prolific government handouts? The profit motive is at least alive and kicking in the sexed-up sanitiser sector,...

While the bushfires continue to rage in parts of the country, you may not be aware that two Australian innovators are revolutionizing the way burns are treated. The...

A blood test for cancer is something of a holy grail in oncology, as it would allow cancers to be found and treated before symptoms show up, without surgery or...

There were some interesting biotech trial results this month. The first is Clinuvel, whose treatment 'Scenesse' was approved last night in the US. Scenesse treats EPP,...

Basil Fawlty famously sought to avoid mentioning the war, but opioid producer Palla Pharma (PAL, $1.03) won’t even try to downplay the tricky topic.The ‘war’ in this...

It has never been less fun to win on a short. By some counts, Biogen's stock collapse marked the latest failure in over a hundred clinical trials based on the...